Treatment Resistant Depression – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Treatment Resistant Depression – Drugs In Development, 2024 report and make more profitable business decisions.
Treatment-resistant depression (TRD) refers to a form of depression that does not adequately respond to standard treatments, such as antidepressant medications or psychotherapy, even after multiple trials of different therapies. It can be a challenging and distressing condition for individuals experiencing persistent depressive symptoms.
Some common characteristics of treatment-resistant depression include inadequate response to antidepressants; persistent symptoms, which can include feelings of sadness, hopelessness, changes in sleep or appetite, fatigue, difficulty concentrating, and loss of interest in activities; and recurrent depressive episodes, wherein individuals experience multiple episodes of depression, each potentially resistant to standard treatments.
The Treatment Resistant Depression drugs in development market research report provide comprehensive information on the therapeutics under development for Treatment Resistant Depression, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Treatment Resistant Depression and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Treatment Resistant Depression | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 67 molecules, with 66 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Treatment Resistant Depression therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Treatment Resistant Depression pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Treatment Resistant Depression treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Alar Pharmaceuticals IncAmorsa Therapeutics Inc
Ancora Bio Inc
Apex Labs Ltd
Atai Life Sciences NV
Autobahn Therapeutics Inc
Avanir Pharmaceuticals Inc
Beckley Psytech Ltd
Better Life Pharmaceuticals Inc
Biomind Labs Inc
Blue Oak Pharmaceuticals Inc
Braxia Scientific Corp
Camino Pharma LLC
Celon Pharma SA
Clearmind Medicine Inc
Compass Pathways Plc
Delix Therapeutics Inc
Denovo Biopharma LLC
Douglas Pharmaceuticals Ltd
Eleusis Holdings Ltd
Ethismos Research Inc
Filament Health Corp
GABA Therapeutics Inc
GH Research PLC
Halucenex Life Sciences Inc
HMNC Holding GmbH
Jiangsu Hansoh Pharmaceutical Group Co Ltd
Johnson & Johnson
Kures Inc
Lophora ApS
Lusaris Therapeutics Inc
Metys Pharmaceuticals AG
miCure Therapeutics Ltd
Mindset Pharma Inc
Mindstate Design Labs
Miralogx LLC
Navitor Pharmaceuticals LLC
NeuraWell Therapeutics Inc
Neurocentrx Pharma Ltd
Neurocrine Biosciences Inc
Novartis AG
PharmaTher Holdings Ltd
PharmoRx Therapeutics Inc
Protagenic Therapeutics Inc
PSYLO Pty Ltd
PsyProtix Inc
Relmada Therapeutics Inc
Reunion Neuroscience Inc
Revixia Life Sciences Inc
Rugen Therapeutics R&D (Shanghai) Co Ltd
Sage Therapeutics Inc
Seelos Therapeutics
Inc.
Sumitomo Pharma America Inc
Sumitomo Pharma Co Ltd
Suven Life Sciences Ltd
SyneuRx International (Taiwan) Corp
Taisho Pharmaceutical Holdings Co Ltd
Viridia Life Sciences Inc
Vivozon Inc
Woke Pharmaceuticals Pty Ltd
XWPharma Ltd
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Treatment Resistant Depression reports